secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0000899923-22-000068
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics Q1 2022 revenue $164.9M, GAAP EPS -$0.26, adjusted EPS -$0.03; reiterates FY2022 guidance
--------------------------------------------------------------------------------

- Revenue $164.9M (+11% YoY ex-divested); GAAP EPS $(0.26) improved from $(0.52); adjusted EPS $(0.03) from $(0.06).
- Cash $339.2M, no debt; adjusted gross margin 71.1%, operating loss $2.8M improved from $3.3M.
- Segment: Hereditary cancer rev $70.9M (-7% YoY); Pharmacogenomics rev $29.3M (+66% YoY); Prenatal +35%.
- Reiterated FY2022 guidance: rev $670-700M; GAAP EPS $(0.90)-(0.70); adj EPS $0.00-$0.20.
- Launched Precise Tumor test, expanded MyRisk to 13 genes, partnered on liquid biopsy test.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992322000068/0000899923-22-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992322000068/mygn-20220505.htm
  HTML page:      https://secwatch.observer/filing/0000899923-22-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer